

Amendment Tool

v1.6 06 December 2021

For office use

QC: No

Section 1: Project information

Short project title*:	TICH-3			
IRAS project ID* (or REC reference if no IRAS project ID is available):	IRAS Project ID 297457			
Sponsor amendment reference number*:	MA_21_23			
Sponsor amendment date* (enter as DD/MM/YY):	30 October 2023			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	This amendment comprises change of PI x 2.			
Project type (select):	Specific study			
	<input type="checkbox"/> Research tissue bank <input type="checkbox"/> Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes	No		
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	NHS/HSC REC			
	<input type="checkbox"/> Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment (i.e. a substantial amendment previously given an unfavourable opinion)?	<input type="checkbox"/> Yes	No		
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	<input type="checkbox"/> England	<input type="checkbox"/> Wales	<input type="checkbox"/> Scotland	<input type="checkbox"/> Northern Ireland
	Yes	<input type="checkbox"/> No	<input type="checkbox"/> No	<input type="checkbox"/> No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes		No	
EudraCT number*:	2021-001050-62			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWoW) pilot)?:	<input type="checkbox"/> Yes		No	
Did the study receive Pharmacy Assurance?:	<input type="checkbox"/> Yes		No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	<input type="checkbox"/> Yes		No	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	<input type="checkbox"/> Yes		No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		<input type="checkbox"/> No	
Did the study have Radiation Assurance OR is Radiation Assurance being sought for the first time because of this amendment?:	<input type="checkbox"/> Yes		No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes		<input type="checkbox"/> No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	<input type="checkbox"/> Yes		No	
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	<input type="checkbox"/> Yes		No	
Did the study involve children OR does the amendment introduce this?:	<input type="checkbox"/> Yes		No	
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes		<input type="checkbox"/> No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	<input type="checkbox"/> Yes		No	
Lead nation for the study:	<input type="checkbox"/> England	<input type="checkbox"/> Wales	<input type="checkbox"/> Scotland	<input type="checkbox"/> Northern Ireland
	Yes	<input type="checkbox"/> No	<input type="checkbox"/> No	<input type="checkbox"/> No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	Yes	Yes	Yes
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes

Section 2: Summary of change(s)

What do you want to update?:	Project information
	New site/PI only

Please note: Only use this option when adding a new site or Principal Investigator (PI) to a clinical trial of an investigational medicinal product (CTIMP). You will not be able to make any other changes at the same time.

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Researchers			
Specific change (select - only available when area of change is selected first)*:	PI - New PI, or temporary arrangements to cover the absence of a PI			
Further information (free text - note that this field will adapt to the amount of text entered):	<p>Dr Sarah Whitehouse (E: sarah.whitehouse5@nhs.net) will replace Dr Anwar (E: ijaz.anwar@nhs.net) and become the new PI at University Hospital of North Tees (North Tees and Hartlepool Hospitals NHS Foundation Trust).</p> <p>Dr Sandeep Bhudda (E: sandeep.buddha@nbt.nhs.uk) will replace Dr Grover (E: Joydeep.Grover@nbt.nhs.uk) and become the new PI at Southmead Hospital (North Bristol NHS Trust).</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Add another change				

Section 3: Declaration(s) and lock for submission


Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Alison Thorpe
Email address*:	sponsor@nottingham.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.



After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

Change 1:	Review bodies														Category:			
	UK wide:					England and Wales:				Scotland:			Northern Ireland:					
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function		HSC REC	HSC Data Guardians	Prisons
					(Y)				(Y)									B

Overall reviews for the amendment:																
Full review:						N					N					
Notification only:						Y					Y					
Overall amendment type:	Non-substantial, no study-wide review required															
Overall Category:	B															